OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr Sells 41,811 Shares

OmniAb, Inc. (NASDAQ:OABIGet Free Report) CEO Matthew W. Foehr sold 41,811 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total value of $135,467.64. Following the completion of the transaction, the chief executive officer now owns 3,749,639 shares in the company, valued at approximately $12,148,830.36. The trade was a 1.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

OmniAb Price Performance

Shares of NASDAQ:OABI opened at $3.20 on Thursday. OmniAb, Inc. has a 1-year low of $3.16 and a 1-year high of $6.55. The stock has a market cap of $451.90 million, a P/E ratio of -5.16 and a beta of -0.10. The firm has a fifty day moving average price of $3.68 and a 200 day moving average price of $4.06.

Hedge Funds Weigh In On OmniAb

Several institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP grew its stake in shares of OmniAb by 6.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock valued at $11,296,000 after purchasing an additional 194,835 shares during the last quarter. Rice Hall James & Associates LLC lifted its holdings in shares of OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after purchasing an additional 163,038 shares during the period. State Street Corp grew its position in OmniAb by 1.7% in the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company’s stock valued at $8,594,000 after buying an additional 34,654 shares during the last quarter. Murchinson Ltd. acquired a new position in OmniAb in the 3rd quarter valued at $4,230,000. Finally, Woodstock Corp raised its position in OmniAb by 1.2% during the 4th quarter. Woodstock Corp now owns 802,578 shares of the company’s stock worth $2,841,000 after buying an additional 9,725 shares during the last quarter. Institutional investors and hedge funds own 72.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on OABI. Benchmark restated a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of OmniAb in a research report on Thursday, November 14th.

Read Our Latest Analysis on OmniAb

OmniAb Company Profile

(Get Free Report)

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.

Featured Stories

Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.